MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31
Medicenna Therapeutics Corp.
Financials through fiscal 2023, year ended Mar 31, 2023Last filing: 20-F on Jun 27, 2023
$0.28−0.02 (-7.63%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Medicenna Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Medicenna Therapeutics filed with the SEC
Announces Closing of CA$20 Million Investment from RA Capital Management
EX-99.1 to Form 6-K
Name and Address of Company
EX-99.2 to Form 6-K
Number of Common Shares Purchasable: 5,141,388
EX-99.3 to Form 6-K
Announces CA$20 Million Investment from RA Capital Management
EX-99.1 to Form 6-K
Interim condensed consolidated financial statements of
EX-99.1 to Form 6-K
For the Three and Nine Months Ended
EX-99.2 to Form 6-K
MNP LLP (“ MNP ”)
EX-99.1 to Form 6-K
Re: Medicenna Therapeutics Corp. (the “Company”)
EX-99.2 to Form 6-K
Medicenna Announces Appointment of New Auditor
EX-99.1 to Form 6-K
NOTICE OF CHANGE OF AUDITOR
EX-99.1 to Form 6-K
We have read the statements made by Medicenna Therapeutics
EX-99.2 to Form 6-K
Medicenna Extends Period to Exercise Certain Warrants
EX-99.1 to Form 6-K
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
EX-99.1 to Form 6-K
Interim condensed consolidated financial statements of
EX-99.1 to Form 6-K
For the Three and Six Months Ended
EX-99.2 to Form 6-K
and Cutback of Management Team
EX-99.1 to Form 6-K
Name and Address of Company
EX-99.2 to Form 6-K
Medicenna Announces Results of Annual and Special Meeting of Shareholders
EX-99.1 to Form 6-K
Annual and Special Meeting of
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K